PT -期刊文章盟Merrikay Oleen-Burkey AU -霍华德Zwibel盟-帕特丽夏Coyle盟-道格拉斯Denney TI -检查预测的身心组件顶部女士的生活质量研究(P07.103) DP - 2012年4月26日TA -神经病学PG - P07.103 P07.103 VI - 78 IP - 1补充4099 - //www.ez-admanager.com/content/78/1_Supplement/P07.103.short 4100 - http:首页//www.ez-admanager.com/content/78/1_Supplement/P07.103.full所以Neurology2012 4月26日;78 AB -目的:评估最有效预测物理组件的分数(pc)和精神组件分数(MCS) SF-12用来评估生活质量治疗优化女士(MS)研究。背景几个病人特征可能与电脑相关的女士和MCS包括病人年龄、残疾状况和水平的疲劳,认为认知障碍和抑郁。设计/方法:潜在参与者顶部女士研究发现与药物疗法专业药房管理计划。签署知情同意表格返回到药店和研究研究网站登记注销生产指令。在基线和定期在24个月,注册参与者收到提醒回应调查,包括SF-12健康调查,自述eds,疲劳程度(FSS)规模,认为赤字问卷(PDQ),和病人健康问卷(PHQ-depression)。自我报告的反应是直接进入到研究数据库。多元回归分析是用来确定个人电脑和MCS的预测因子。Results: The array of patient characteristics that was highly effective at predicting the PCS included patient age, self-reported EDSS, and scores on the FSS, PDQ, and PHQ (adjusted R2 = .620, p < .001). The unique predictors of the PCS were the self-reported EDSS score (p < .0001) and FSS score (p < .0001) as independent predictors. The same array of predictors was also highly effective at predicting the MCS (adjusted R2 = .467, p < .001). However, the unique predictors of the MCS were the self-reported EDSS (p = .055) and the mediating variable, PHQ (p < .0001).Conclusions: While the same set of patient characteristics was highly effective at predicting the PCS and MCS, depression was a unique and mediating variable between disability and MCS while the PCS had two independent predictors: disability and fatigue.Supported by: Teva Pharmaceuticals.Disclosure: Dr. Oleen-Burkey has received personal compensation for activities with Teva Neuroscience. Dr. Oleen-Burkey holds stock and/or stock options in Pfizer, Inc and Teva Neuroscience. Dr. Oleen-Burkey has received research support from Teva Neuroscience. Dr. Zwibel has received personal compensation for activities with Serono, Inc., and Teva Neuroscience. Dr. Zwibel has received research support from Teva Neuroscience. Dr. Coyle has received personal compensation for activities with Acorda Therapeutics, Avanir Pharmaceuticals, Bayer Pharmaceuticals Corporation, Biogen Idec, Genzyme Corporation, Novartis, Questcor, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neuroscience. Dr. Coyle has received personal compensation in an editorial capacity for NEURA. Dr. Coyle has received research support from Serono, Inc., Novartis, and Sanofi-Aventis Pharmaceuticals, Inc. Dr. Denney has received personal compensation for activities with Teva Neuroscience Inc. as a consultant.Dr. Denney has received research support from Serono Inc.Thursday, April 26 2012, 14:00 pm-18:30 pm